Prosight Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
Prosight Management's ALNY Position: Q3 2026 in Review
Prosight Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 62% in Q3 2026, selling an estimated $15.5M and leaving 37,000 shares worth $9.13M. The position accounts for 1.77% of the portfolio, ranked #19.
Prosight Management first reported a position in ALNY in Q4 2021 and has held it in 6 quarters since. The position peaked at $29.5M in Q2 2026. 729 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.
- Prosight Management held 37,000 shares of Alnylam Pharmaceuticals worth $9.13M as of Q3 2026.
- Prosight Management sold 61,080 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $15.5M.
- Alnylam Pharmaceuticals made up 1.77% of Prosight Management's portfolio in Q3 2026, its #19 holding.
- Prosight Management first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 6 quarters since.
- Prosight Management's Alnylam Pharmaceuticals position peaked at $29.5M in Q2 2026.
- 729 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.
Based on Prosight Management's 13F filing for Q3 2026, filed 13 Nov 2026.